INVERSINE
LOE Approachingmecamylamine hydrochloride
NDAORALTABLETPriority Review
Approved
Mar 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
INVERSINE (mecamylamine hydrochloride) is clinical pharmacology mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. Approved for hypertension. First approved in 1956.
Drug data last refreshed 8h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVERSINE (mecamylamine hydrochloride) is an oral ganglionic blocking agent approved in 1956 for treating hypertension. It reduces blood pressure through ganglionic blockade with gradual onset (30 minutes to 2 hours) and prolonged effect (6–12+ hours). The drug is almost completely absorbed orally and excreted unchanged in urine, with renal elimination influenced by urinary pH.
LOE Approaching
Product approaching loss of exclusivity with minimal current commercial data; likely a legacy brand with reduced team investment and commercial support.
Mechanism of Action
CLINICAL PHARMACOLOGY Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a longlasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood…
Indications (1)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.